Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study

被引：0
|
作者：
Papanicolaou, Genovefa A. [1 ]
Silveira, Fernanda P. [2 ]
Langston, Amelia A. [3 ]
Pereira, Marcus R. [4 ]
Avery, Robin K. [5 ]
Wijatyk, Anna [6 ]
Wu, Jingyang J. [6 ]
Boeckh, Michael J. [7 ]
Marty, Francisco M. [8 ]
Villano, Stephen [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Winship Canc Inst, Atlanta, GA USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Shire, Lexington, MA USA
[7] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[9] Shire, Wayne, PA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2017年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
45
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [1] Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
    Papanicolaou, Genovefa A.
    Silveira, Fernanda P.
    Langston, Amelia A.
    Pereira, Marcus R.
    Avery, Robin K.
    Uknis, Marc
    Wijatyk, Anna
    Wu, Jingyang
    Boeckh, Michael
    Marty, Francisco M.
    Villano, Stephen
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (08) : 1255 - 1264
  • [2] Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study
    Pereira, M.
    Silveira, F.
    Papanicolaou, G.
    Langston, A.
    Avery, R.
    Wijatyk, A.
    Wu, J.
    Boeckh, M.
    Marty, F.
    Villano, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 405 - 405
  • [3] Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients
    Maertens, Johan A.
    Cordonnier, Catherine
    Jaksch, Peter
    Poire, Xavier
    Wu, Jingyang J.
    Wijatyk, Anna
    Saliba, Faouzi
    Witzke, Oliver
    Villano, Stephen
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S180 - S181
  • [4] Maribavir versus valganciclovir for pre-emptive treatment of cytomegalovirus viraemia: a randomized, dose-ranging, phase 2 study among haematopoietic stem cell transplant and solid organ transplant recipients
    Maertens, J.
    Cordonnier, C.
    Jaksch, P.
    Poire, X.
    Wu, J.
    Wijatyk, A.
    Saliba, F.
    Faouzi
    Witzke, O.
    Villano, S.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S100 - S102
  • [5] Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
    Ogawa, Lauren
    Morinishi, Chelsea
    Multani, Ashrit
    Gaynor, Pryce
    Beaird, Omer E.
    Pham, Christine
    Schaenman, Joanna M.
    VIRUSES-BASEL, 2024, 16 (12):
  • [6] Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
    Winston, Drew J.
    Young, Jo-Anne H.
    Pullarkat, Vinod
    Papanicolaou, Genovefa A.
    Vij, Ravi
    Vance, Estil
    Alangaden, George J.
    Chemaly, Roy F.
    Petersen, Finn
    Chao, Nelson
    Klein, Jared
    Sprague, Kellie
    Villano, Stephen A.
    Boeckh, Michael
    BLOOD, 2008, 111 (11) : 5403 - 5410
  • [7] EXPERIENCE WITH THE USE OF MARIBAVIR IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS (CMV)
    Fernandez Perez, Monica
    Ceballos Bolanos, Candela
    Oiartzabal Ormategui, Itziar
    Arratibel Zalacain, Nerea
    Millacoy Austenrritt, Pamela
    Aranguren Ostolaza, Marina
    Viguria Alegria, Maria Cruz
    Panizo Santos, Carlos Manuel
    BONE MARROW TRANSPLANTATION, 2024, 59 : 475 - 476
  • [8] Phase 3 Randomized, double-blind Study of Maribavir Compared with Valganciclovir for Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic stem-cell Transplant (HSCT) Recipients (Study Design)
    Maertens, Johan
    Alain, Sophie
    Avery, Robin
    Murray, Rose Ann
    Wu, Jingyang
    Ljungman, Per
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 500 - 500
  • [9] Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients
    Imlay, Hannah N.
    Kaul, Daniel R.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) : 156 - 160
  • [10] Prophylaxis against cytomegalovirus infections with oral maribavir in allogeneic stem cell transplant recipients: Results of a randomized, double-blind, placebo-controlled trial.
    Winston, Drew
    van Burik, Jo-Anne
    Pullarkat, Vinod
    Papanicolaou, Genovefa
    Vij, Ravi
    Vance, Estil
    Alangaden, George
    Chemaly, Roy
    BLOOD, 2006, 108 (11) : 179A - 179A
12345